A neurophysiological study of near infrared spectroscopy haemoencephalography neurofeedback treatment in Alzheimer's disease and related cognitive impairments

INTERVENTION: Phase 1 ‐ establish the neurofeedback protocols, monitor treatment effects and side effects and confirm the number of participants required for Phase 2. Phase 2 ‐ baseline and post treatment fMRI on five groups of patients AMCI treated with NIRS‐HEG biofeedback, AMCI treated with placebo NIRS‐HEG biofeedback, elderly controls treated with NIRS‐HEG biofeedback, mild AD treated with NIRS‐HEG and mild AD treated with placebo NIRS‐HEG biofeedback. CONDITION: Nervous System Diseases: Alzheimer's disease ; Nervous System Diseases ; Alzheimer's disease PRIMARY OUTCOME: Change in cognition and/or behaviour following treatment. SECONDARY OUTCOME: Not provided at time of registration INCLUSION CRITERIA: Phase 1: 10 patients with AMCI and 10 with mild AD Phase 2: 12‐15 patients in each group depending upon the results of phase 1 of the study